PORTLAND, OR--(Marketwire - October 24, 2012) - MolecularMD Corp
. announced today that presentations pertaining to clinical validation of Next Generation Sequencing platforms and advances in non-invasive detection of solid tumors will be highlighted at the Association for Molecular Pathology (AMP) Annual Meeting on Genomic Medicine and at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The presentations demonstrate MolecularMD's leadership as a provider of innovative and reliable molecular diagnostic solutions that improve and advance personalized medicine for cancer patients.
The Association for Molecular Pathology (AMP) Annual Meeting on Genomic Medicine to be held in Long Beach, CA on October 25-27, 2012:
- MolecularMD scientists will present poster number TT43 entitled "Analytical Validation of Ion AmpliSeq Cancer Panel 2.0" on Saturday, October 27th.
- MolecularMD scientists will present poster number ST57 entitled "Liquid Biopsy: the application of allele-specific PCR (AS-PCR) and mutation-directed SNaPshot assay to detect BRAF and NRAS mutant DNA in peripheral blood from metastatic melanoma patients" on Saturday, October 27th. This work was performed in collaboration with the laboratory of Dr. David Polsky at New York University.
The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Dublin, Ireland, November 6-9, 2012:
- MolecularMD scientists will present poster number 021 (abstract number 450) entitled "Non-invasive Absolute Quantification of EGFR Activating Mutation L858R and Gatekeeper Mutation T790M in NSCLC Plasma Samples Using Droplet Digital PCR" as part of the "Biomarkers" poster session on Friday, November 9th.
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD incorporates gold-standard and innovative technologies in providing its partners with the highest quality results. Assays are designed to meet clinical trial needs, and MolecularMD has appropriate systems and standards in place to enable development of companion diagnostic tests in conjunction with partners' novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Brian Druker, director of the Knight Cancer Center at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation.